Cargando…

Risk Factors for High-Titer Inhibitor Development in Children with Hemophilia A: Results of a Cohort Study

Among the discussed risk factors for high-titre inhibitor (HRI) development in patients with hemophilia A (HA) are high dose FVIII replacement therapy and use of recombinant FVIII concentrates (rFVIII). The aim of this study was to evaluate the aforementioned risk factors for HRI development in chil...

Descripción completa

Detalles Bibliográficos
Autores principales:	Halimeh, Susan, Bidlingmaier, Christoph, Heller, Christine, Gutsche, Sven, Holzhauer, Susanne, Kenet, Gili, Kurnik, Karin, Manner, Daniela, Iorio, Alfonso, Nowak-Göttl, Ulrike
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2013
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3807559/ https://www.ncbi.nlm.nih.gov/pubmed/24199202 http://dx.doi.org/10.1155/2013/901975

Ejemplares similares

Health-Related Quality of Life in Children and Adolescents with Hereditary Bleeding Disorders and in Children and Adolescents with Stroke: Cross-Sectional Comparison to Siblings and Peers
por: Neuner, Bruno, et al.
Publicado: (2016)

Risk factors for recurrent venous thromboembolism in the European collaborative paediatric database on cerebral venous thrombosis: a multicentre cohort study
por: Kenet, Gili, et al.
Publicado: (2007)

Inhibitor incidence in an unselected cohort of previously untreated patients with severe hemophilia B: a PedNet study
por: Male, Christoph, et al.
Publicado: (2020)

Thrombin generation and implications for hemophilia therapies: A narrative review
por: Sidonio, Robert F., et al.
Publicado: (2022)

Emicizumab state‐of‐the‐art update
por: Mahlangu, Johnny, et al.
Publicado: (2022)

Women with Hemophilia: Case Series of Reproductive Choices and Review of Literature
por: Lalezari, Shadan, et al.
Publicado: (2021)

The safety and efficacy of N8-GP (turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A
por: Male, Christoph, et al.
Publicado: (2022)

Long‐term safety and efficacy of N8‐GP in previously treated pediatric patients with hemophilia A: Final results from pathfinder5
por: Šaulytė Trakymienė, Sonata, et al.
Publicado: (2020)

Challenges and successes in the treatment of hemophilia: the story of a patient with severe hemophilia A and high-titer inhibitors
por: Saba, Hussain I, et al.
Publicado: (2011)

Cerebral Venous Thrombosis in the Mediterranean Area in Children
por: Menascu, S., et al.
Publicado: (2011)

Mode of delivery in hemophilia: vaginal delivery and Cesarean section carry similar risks for intracranial hemorrhages and other major bleeds
por: Andersson, Nadine G., et al.
Publicado: (2019)

Does Treatment of Hepatitis C Reduce Inhibitor Titers in Hemophilia A?
por: Atay, Memiş Hilmi, et al.
Publicado: (2022)

Real-World Data on Bleeding Patterns of Hemophilia A Patients Treated with Emicizumab
por: Levy-Mendelovich, Sarina, et al.
Publicado: (2021)

Management of surgery in persons with hemophilia A receiving emicizumab prophylaxis: data from a national hemophilia treatment center
por: Cohen, Omri, et al.
Publicado: (2023)

Infrared Thermography as a Non-Invasive Tool to Explore Differences in the Musculoskeletal System of Children with Hemophilia Compared to an Age-Matched Healthy Group
por: Seuser, Axel, et al.
Publicado: (2018)

Factor VIII inhibitors in hemophilia A treated with emicizumab: longitudinal follow-up of outcomes
por: Levy-Mendelovich, Sarina, et al.
Publicado: (2023)

Long-Acting Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Children: Results of a Phase 3 Trial
por: Kenet, Gili, et al.
Publicado: (2016)

Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies for Hemophilia A Patients
por: Khalilian, Sheyda, et al.
Publicado: (2020)

MicroRNA and Hemophilia-A Disease: Bioinformatics Prediction and Experimental Analysis
por: Rezaei, Halimeh, et al.
Publicado: (2021)

Molecular Mechanisms of Skewed X-Chromosome Inactivation in Female Hemophilia Patients—Lessons from Wide Genome Analyses
por: Dardik, Rima, et al.
Publicado: (2021)

Four Decades of Carrier Detection and Prenatal Diagnosis in Hemophilia A: Historical Overview, State of the Art and Future Directions
por: Dardik, Rima, et al.
Publicado: (2023)

Recombinant porcine factor VIII corrects thrombin generation in vitro in plasma from patients with congenital hemophilia A and inhibitors
por: Négrier, Claude, et al.
Publicado: (2022)

BAY 81-8973 Efficacy and Safety in Previously Untreated and Minimally Treated Children with Severe Hemophilia A: The LEOPOLD Kids Trial
por: Ljung, Rolf, et al.
Publicado: (2023)

Inherited Thrombophilia in Pediatric Venous Thromboembolic Disease: Why and Who to Test
por: van Ommen, C. Heleen, et al.
Publicado: (2017)

Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors
por: Tjønnfjord, Geir E, et al.
Publicado: (2007)

Conservative therapy for spinal epidural hematoma in a child with hemophilia A with high-titer VIII inhibitors
por: Wang, Guige, et al.
Publicado: (2021)

International pediatric thrombosis network to advance pediatric thrombosis research: Communication from the ISTH SSC subcommittee on pediatric and neonatal thrombosis and hemostasis
por: van Ommen, C. Heleen, et al.
Publicado: (2021)

Hemophilia trials in the twenty‐first century: Defining patient important outcomes
por: Konkle, Barbara A., et al.
Publicado: (2019)

Emicizumab prophylaxis in a Korean child with severe hemophilia A and high titer inhibitor: a case report
por: Ahn, Ji Hyun, et al.
Publicado: (2021)

Design of a Real-World Observational Study in Previously Untreated and Minimally Treated Hemophilia A Patients: Protect-NOW
por: Oldenburg, Johannes, et al.
Publicado: (2023)

Safety and efficacy of long‐term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: A phase 3b, multicenter, single‐arm study (STASEY)
por: Jiménez‐Yuste, Víctor, et al.
Publicado: (2022)

Recurrent stroke: the role of thrombophilia in a large international pediatric stroke population
por: deVeber, Gabrielle, et al.
Publicado: (2019)

Pharmacokinetic‐tailored approach to hemophilia prophylaxis: Medical decision making and outcomes
por: Croteau, Stacy E., et al.
Publicado: (2020)

Extended half‐life factor VIII concentrates in adults with hemophilia A: Comparative pharmacokinetics of two products
por: Teitel, Jerome, et al.
Publicado: (2021)

The impact of extended half‐life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B
por: Sun, Haowei (Linda), et al.
Publicado: (2021)

PB2647: USE OF EMICIZUMAB FOR THE TREATMENT OF ACQUIRED HEMOPHILIA A: A SYSTEMATIC REVIEW
por: Al-Housni, Zainab, et al.
Publicado: (2023)

Joint Bleeding Tendencies in Adult Patients With Hemophilia: It’s Not All Pharmacokinetics
por: Zhou, Jenny Y., et al.
Publicado: (2019)

Low‐dose immune tolerance induction for children with hemophilia A with poor‐risk high‐titer inhibitors: A pilot study in China
por: Li, Zekun, et al.
Publicado: (2019)

Low‐dose immune tolerance induction in children with severe hemophilia A with high‐titer inhibitors: Type of factor 8 mutation and outcomes
por: Sun, Jie, et al.
Publicado: (2022)

Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review
por: Yu, Jacky K., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_cl7ou6htaph4uecbf407iddi94